Impact of chronic kidney disease and diabetes on percutaneous coronary intervention outcomes

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Abnormalities in glucose metabolism (diabetes) and chronic kidney disease (CKD) significantly complicate percutaneous coronary intervention (PCI) outcomes.
• Diabetes contributes to hyperglycemia, impaired microvascular perfusion, and a prothrombotic/proinflammatory state, exacerbating cardiovascular disease (CVD) risks.
• CKD is linked to accelerated atherosclerosis, increased CVD mortality and morbidity, and heightened risks during PCI procedures.

Purpose of the Study:

• To evaluate therapeutic strategies for patients with concurrent diabetes or CKD undergoing PCI.
• To identify interventions that mitigate the increased risks associated with these comorbidities in PCI patients.

Main Methods:

• Review of clinical data examining treatment outcomes in PCI patients with glucose metabolism disturbances or CKD.
• Analysis of the impact of specific pharmacological agents and stent technologies on patient outcomes.

Main Results:

• Clinical evidence supports the use of abciximab in PCI patients with diabetes or CKD.
• Drug-eluting stents have been shown to decrease rates of target vessel revascularization and restenosis.

Conclusions:

• The interplay between renal dysfunction, metabolic disturbances, and CVD (renal dysmetabolic syndrome) requires careful consideration in PCI treatment planning.
• Abciximab demonstrates clinical utility for managing PCI patients with glucose metabolism abnormalities or CKD.
• Drug-eluting stents are effective in reducing restenosis and the need for repeat revascularization in this complex patient population.